Advertisement

Topics

ASH 2017: Janssen to Present 40 Abstracts with New Data on Darzalex, Imbruvica, and Other Compounds from its Portfolio

14:00 EST 8 Nov 2017 | Drug Discovery Development

DARZALEX was the first CD38-directed antibody to receive regulatory approval to treat relapsed or refractory multiple myeloma.
Contributed Author: 
Janssen
Topics: 

Original Article: ASH 2017: Janssen to Present 40 Abstracts with New Data on Darzalex, Imbruvica, and Other Compounds from its Portfolio

NEXT ARTICLE

More From BioPortfolio on "ASH 2017: Janssen to Present 40 Abstracts with New Data on Darzalex, Imbruvica, and Other Compounds from its Portfolio"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...